Stanley B Kaye
Overview
Explore the profile of Stanley B Kaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Permuth-Wey J, Lawrenson K, Shen H, Velkova A, Tyrer J, Chen Z, et al.
Nat Commun
. 2013 Mar;
4:1627.
PMID: 23535648
Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized that variants in the 3'...
12.
White K, Vierkant R, Fogarty Z, Charbonneau B, Block M, Pharoah P, et al.
Cancer Epidemiol Biomarkers Prev
. 2013 Mar;
22(5):987-92.
PMID: 23513043
Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian...
13.
Banerjee S, Kaye S
Clin Cancer Res
. 2013 Jan;
19(5):961-8.
PMID: 23307860
The treatment of ovarian cancer is set to undergo rapid changes, as strategies incorporating molecular targeted therapies begin to take shape. These are based on a better appreciation of approaches...
14.
Kaye S, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al.
Clin Cancer Res
. 2012 Oct;
18(23):6509-18.
PMID: 23032746
Purpose: Hedgehog pathway inhibition has been suggested as a potential maintenance treatment approach in ovarian cancer through disruption of tumor-stromal interactions. Vismodegib is an orally available Hedgehog pathway inhibitor with...
15.
Krasner C, Poveda A, Herzog T, Vermorken J, Kaye S, Nieto A, et al.
Gynecol Oncol
. 2012 Jul;
127(1):161-7.
PMID: 22765965
Objective: Trabectedin in combination with PLD improves progression-free survival (PFS) and overall response rate (ORR) in comparison to PLD alone in patients with relapsed ovarian cancer (J Clin Oncol; 2010...
16.
Monk B, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F, et al.
Eur J Cancer
. 2012 May;
48(15):2361-8.
PMID: 22541893
Aim: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:3107-14). Methods: Women, stratified by performance...
17.
Papadatos-Pastos D, Dedes K, de Bono J, Kaye S
Oncologist
. 2011 Sep;
16(10):1413-21.
PMID: 21948654
Androgen receptors are frequently expressed in epithelial ovarian cancer (EOC). Their role in the development of EOC is not fully understood. In the present review we first discuss the epidemiological...
18.
Poveda A, Kaye S, McCormack R, Wang S, Parekh T, Ricci D, et al.
Gynecol Oncol
. 2011 Jun;
122(3):567-72.
PMID: 21664658
Objective: Serial circulating tumor cell (CTC) counts have demonstrated predictive and prognostic value in patients with metastatic breast, colorectal, and prostate cancer. In a phase III study of pegylated liposomal...
19.
Amankwah E, Wang Q, Schildkraut J, Tsai Y, Ramus S, Fridley B, et al.
PLoS One
. 2011 Jun;
6(5):e19642.
PMID: 21637745
Alterations in stromal tissue components can inhibit or promote epithelial tumorigenesis. Decorin (DCN) and lumican (LUM) show reduced stromal expression in serous epithelial ovarian cancer (sEOC). We hypothesized that common...
20.
Tan D, Iravani M, McCluggage W, Lambros M, Milanezi F, Mackay A, et al.
Clin Cancer Res
. 2011 Mar;
17(6):1521-34.
PMID: 21411445
Purpose: Ovarian clear cell carcinomas (OCCC) are a drug-resistant and aggressive type of epithelial ovarian cancer. We analyzed the molecular genetic profiles of OCCCs to determine whether distinct genomic subgroups...